i}, {range™: {length:394,start:0},textStyle:_ anf-ts-1}],layout:default-—
body, role: body, text:An examination of Celgened€™s aggressive promotion of
Revlimid and its predecessor, Thalomid, while Mr. Hugin was a top executive at the
company, including its chief executive for six years, reveals many of the controversial
financial and legal tactics that have tarnished the industryd€™s reputation, from
marketing drugs for unapproved uses to raising prices and fighting off generic
competitors., type: text}, {(additions: [{URL:https://www.nytimes.com/2017/07/25/h
ealth/celgene-to-pay-280-million-to-settle-fraud-suit-over-cancer
drugs.html?partner=applenewsé&ad

keywords=APPLEMOBILE&region=written throughé&asset_id=100000006090758, range™: {length
793, Start:19}, type? Link }],identifier: ant-body—

12, inlineTextStyles:[{range:{length:362,start:0},textStyle: anf-ts-

im}, {range:{Llength:362,start:0},textStyle: anf-ts-1}],layout:default-

body, role:body, text:Last year, Celgene paid $280 million to settle a whistle-
blower lawsuit claiming it had inappropriately promoted Revlimid and Thalomid to treat
a range of cancers beyond what the Food and Drug Administration had approved. Several
generic drug companies have sued the company claiming that Celgene denied them access
to drug samples needed to make cheaper
copies.,type™:text}, {additions: [{URL:https://www. youtube.com/watch?v=RIfsé6hthw

Go, range: {length:71, start :138},type:Link}],identifier: anf-body-
13,inlineTextStyles: [{range:{length:334,start:0},textStyle: anf-ts-
I}, {range™: {length:334,start:0},textStyle: anf-ts-1}],layout:default-

body, role:body, text:Mr. Hugin has also been targeted by a super PAC run by a
cancer patient taking Revlimid that launched a $1.5 million advertising campaign
criticizing steep price hikes of cancer drugs during Mr. Hugind€™s tenure at Celgen
And the Menendez campaign has attacked him around drug prices, personal profits and the

$280 million settlement.,type:text}, {bannerType:any,identifier: anf-
banner advertisement-2,layout: ComponentLayout—

4,role:banner advertisement, type:banner advertisement}, {identifier™: anf-
body-14, inlineTextStyles: [{range™:{length:38,start:0},textStyle: anf-ts-
I}, {range™: {length:38,start:0},textStyle: anf-ts-1}],layout:default—
body, role:body, text:Mr. Hugin has dismissed the

criticism.,type:text}, {identifier: anf-body-
15,inlineTextStyles:[{range:{length:317,start:0},textStyle: anf-ts-

i}, {range™:{length:317,start:0},textStyle: anf-ts-1}],layout:default-—
body, role: body, text: a€eNew Jersey voters are a lot smarter than my opponent

gives them credit for,d4€ Mr. Hugin said in a statement. A4€eThey understand that it
costs billions of dollars in research and development, and years of hard work by
hundreds of researchers and scientists, to develop medicines that successfully treat

and cure cancer.a€,type:text}, {identifier: anf-body-

16, inlineTextStyles:[{range:{length:237,start:0},textStyle: anf-ts-

I}, {range™: {length:237,start:0},textStyle:_anf-ts-1}],layout:default-—
body, role:body, text:Some experts are not so sure. Patrick Murray, director of

the Monmouth University Poll, noted that despite the fact that many large drug
companies are based in New Jersey, public opinion in the state likely mirrors the

national attitude.,type™:text}, {identifier: anf-body-
17,inlineTextStyles: [{range:{length:228,start:0},textStyle: anf-ts-
i}, {range™: {length:228,start:0},textStyle: anf-ts-1}],layout:default-

body, role: body, text: a€eConcern about being able to afford health care is the
top issue mentioned by voters in our polling for this yeara€™s midterm, in large part
because of rising drug costs,a4€ Mr. Murray said. d€eThis provides an opening for
Menendez. ae™mae™, type™:text}, {components: [{caption:Mr. Menendez has attacked
Mr. Hugind€™s record as a pharmaceutical executive, accusing him of profiting from
major price increases for cancer drugs. Bryan Anselm for The New York

Times, captionComponent:{text:Mr. Menendez has attacked Mr. Hugind€™s record as a
pharmaceutical executive, accusing him of profiting from major price increases for
cancer drugs. Bryan Anselm for The New York

Times},identifier™:100000006098032 Sba8b804lidfc, imageIdentifier:5e5526aaedbd7aft
8c8bhade0a70blidad, layout:fullbleed-

image, role:photo, type: scalable image}, {identifier: anf-caption-
2,inlineTextStyles: [{range: {length:36, start:146}, textStyle: photo-
credit}],layout:default-caption, role: caption, text:Mr. Menendez has attacked

Mr. Hugind€™s record as a pharmaceutical executive, accusing him of profiting from
major price increases for cancer drugs. Bryan Anselm for The New York Times

,type™:text}],identifier: anf-container-1, layout: image-
container, role:container, type:container}, {identifier: anf-body-
18,inlineTextStyles:[{range:{length:277,start:0},textStyle: anf-ts-

HOUSE_OVERSIGHT_028416
